Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Share-based Compensation (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Share-based Compensation data on record, last reported at $2.2 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 29.46% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $9.1 million, up 67.82%, while the annual FY2025 figure was $9.1 million, 67.82% up from the prior year.
  • Share-based Compensation reached $2.2 million in Q4 2025 per TLSI's latest filing, down from $3.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.4 million in Q3 2025 and bottomed at $68000.0 in Q2 2023.
  • Average Share-based Compensation over 4 years is $1.2 million, with a median of $1.3 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: skyrocketed 1775.0% in 2024, then rose 29.46% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $117000.0 in 2022, then skyrocketed by 754.7% to $1.0 million in 2023, then soared by 69.7% to $1.7 million in 2024, then rose by 29.46% to $2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $2.2 million in Q4 2025, $3.4 million in Q3 2025, and $1.9 million in Q2 2025.